

# Stacey Shiovitz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5366834/publications.pdf>

Version: 2024-02-01

27  
papers

706  
citations

687363

13  
h-index

642732

23  
g-index

27  
all docs

27  
docs citations

27  
times ranked

1591  
citing authors

#	ARTICLE	IF	CITATIONS
1	CpG Island Methylator Phenotype Is Associated With Response to Adjuvant Irinotecan-Based Therapy for Stage III Colon Cancer. <i>Gastroenterology</i> , 2014, 147, 637-645.	1.3	118
2	Molecular phenotypes of colorectal cancer and potential clinical applications. <i>Gastroenterology Report</i> , 2015, 3, gov046.	1.3	105
3	Cancer Misinformation and Harmful Information on Facebook and Other Social Media: A Brief Report. <i>Journal of the National Cancer Institute</i> , 2022, 114, 1036-1039.	6.3	74
4	Stage IV colorectal cancer primary site and patterns of distant metastasis. <i>Cancer Epidemiology</i> , 2017, 48, 92-95.	1.9	62
5	Timing of Aspirin and Other Nonsteroidal Anti-Inflammatory Drug Use Among Patients With Colorectal Cancer in Relation to Tumor Markers and Survival. <i>Journal of Clinical Oncology</i> , 2017, 35, 2806-2813.	1.6	57
6	Lynch Syndrome: From Screening to Diagnosis to Treatment in the Era of Modern Molecular Oncology. <i>Annual Review of Genomics and Human Genetics</i> , 2019, 20, 293-307.	6.2	39
7	Frequent PIK3CA Mutations in Colorectal and Endometrial Tumors With 2 or More Somatic Mutations in Mismatch Repair Genes. <i>Gastroenterology</i> , 2016, 151, 440-447.e1.	1.3	36
8	Initiation of universal tumor screening for <sc>L</sc>ynch syndrome in colorectal cancer patients as a model for the implementation of genetic information into clinical oncology practice. <i>Cancer</i> , 2016, 122, 393-401.	4.1	28
9	Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer Treated With Adjuvant Oxalipatin. <i>Clinical Colorectal Cancer</i> , 2016, 15, 164-169.	2.3	24
10	Targeted therapy in gastroesophageal cancers: past, present and future: Figure 1.. <i>Gastroenterology Report</i> , 2015, 3, gov052.	1.3	21
11	Clinicopathologic Risk Factor Distributions for <i>MLH1</i> Promoter Region Methylation in CIMP-Positive Tumors. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 68-75.	2.5	21
12	Long-term weight loss after colorectal cancer diagnosis is associated with lower survival: The Colon Cancer Family Registry. <i>Cancer</i> , 2017, 123, 4701-4708.	4.1	20
13	Use of perioperative chemotherapy in colorectal cancer metastatic to the liver. <i>Gastroenterology Report</i> , 2019, 7, 301-311.	1.3	16
14	Molecular Markers Predictive of Chemotherapy Response in Colorectal Cancer. <i>Current Gastroenterology Reports</i> , 2015, 17, 431.	2.5	13
15	Head circumference in the clinical detection of PTEN hamartoma tumor syndrome in a clinic population at high-risk of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 124, 459-465.	2.5	11
16	High Risk of Colorectal and Endometrial Cancer in Ashkenazi Families With the MSH2 A636P Founder Mutation. <i>Gastroenterology</i> , 2011, 140, 1919-1926.	1.3	11
17	Cancer-Directed Therapy and Hospice Care for Metastatic Cancer in American Indians and Alaska Natives. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1138-1143.	2.5	10
18	Development of FamilyTalk: an Intervention to Support Communication and Educate Families About Colorectal Cancer Risk. <i>Journal of Cancer Education</i> , 2020, 35, 470-478.	1.3	10

#	ARTICLE	IF	CITATIONS
19	Biomarker-driven and molecular targeted therapies for colorectal cancers. <i>Seminars in Oncology</i> , 2018, 45, 124-132.	2.2	9
20	Cancer Stage in American Indians and Alaska Natives Enrolled in Medicaid. <i>American Journal of Preventive Medicine</i> , 2016, 51, 368-372.	3.0	7
21	Radiation Therapy Dose Escalation to Clinically Involved Pelvic Sidewall Lymph Nodes in Locally Advanced Rectal Cancer. <i>Advances in Radiation Oncology</i> , 2019, 4, 478-486.	1.2	7
22	Colorectal Cancer Anatomical Site and Sleep Quality. <i>Cancers</i> , 2021, 13, 2578.	3.7	4
23	SWOG S1820: Altering Intake, Managing Symptoms for bowel dysfunction in survivors of Rectal Cancer (The AIMS-RC intervention trial). <i>Contemporary Clinical Trials Communications</i> , 2021, 22, 100768.	1.1	2
24	Genetic Predictors of Severe Skin Toxicity in Patients with Stage III Colon Cancer Treated with Cetuximab: NCCTG N0147 (Alliance). <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 404-411.	2.5	1
25	The Utility of Circulating Tumor DNA (ctDNA) Monitoring in Cancer Patients Who Are Pregnant or Planning to Become Pregnant. <i>Case Reports in Obstetrics and Gynecology</i> , 2022, 2022, 1-5.	0.3	0
26	Evaluation of methylated DCR1 as a biomarker for response to adjuvant irinotecan-based therapy in stage III colon cancer: cancer and leukaemia Group B 89803 (Alliance). <i>Epigenetics</i> , 2022, , 1-11.	2.7	0
27	Updated clinical outcomes from ULI-EAP-100, an intermediate expanded access program for ulixertinib (BVD-523).. <i>Journal of Clinical Oncology</i> , 2022, 40, e15101-e15101.	1.6	0